Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Cash from Financing Activities (2016 - 2026)

Pharma-Bio Serv's Cash from Financing Activities history spans 17 years, with the latest figure at -$1681.0 for Q1 2026.

  • For Q1 2026, Cash from Financing Activities changed N/A year-over-year to -$1681.0; the TTM value through Jan 2026 reached -$1.8 million, down 1.55%, while the annual FY2025 figure was -$1.8 million, 1.03% down from the prior year.
  • Cash from Financing Activities reached -$1681.0 in Q1 2026 per PBSV's latest filing, up from -$9202.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of -$792.0 in Q4 2023 to a low of -$1.8 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is -$626663.6, with a median of -$8197.5 recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: tumbled 62248.3% in 2022, then surged 66.71% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$2379.0 in 2022, then skyrocketed by 66.71% to -$792.0 in 2023, then tumbled by 120.58% to -$1747.0 in 2024, then tumbled by 426.73% to -$9202.0 in 2025, then skyrocketed by 81.73% to -$1681.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Cash from Financing Activities are -$1681.0 (Q1 2026), -$9202.0 (Q4 2025), and -$5004.0 (Q3 2025).